Use of Ferumoxytol enhanced Magnetic Resonance Angiography for cardiovascular assessment in late-stage chronic kidney disease by Stoumpos, Sokratis et al.











































































































































































































































































































































































Background	 –	 The	 usually	 employed	 methods	 for	 non-invasive	 cardiovascular	 imaging	 using	
Magnetic	Resonance	 Imaging	 (MRI)	or	Computed	Tomography	 (CT)	 carry	potential	 risks	 for	kidney	
disease	 patients.	 An	 alternative	 contrast	 agent	 is	 needed	 to	 optimise	 imaging	 results	 while	
minimising	risks	in	this	vulnerable	patient	group.	Ferumoxytol	originally	developed	as	a	MRI	contrast	
agent	 and	 is	 currently	 licensed	 in	 the	 USA	 and	 Canada	 for	 iron-replacement	 therapy	 primarily	 in	
patients	 with	 kidney	 disease,	 still	 has	 excellent	 potential	 as	 MRI	 contrast	 agent	 in	 assessing	 the	
heart,	central	and	peripheral	vessels.	
	
Objectives	 -	 To	 determine	 the	 quality	 and	 clinical	 yield	 of	 Ferumoxytol-enhanced	 Magnetic	





Setting	 and	 Participants	 -	 Patients	 with	 late-stage	 kidney	 disease	 undergoing	 conventional	


























Invited to participate: 
• Meet inclusion criteria 
Informed consent (Form A) 
Analysis 
Primary Outcome 
• Comparison of FeMRA with standard imaging techniques in 
imaging quality and diagnostic accuracy in assessment of vascular 
anatomy (all cohorts) 
• Change in cardiac anatomical and functional parameters after 
AVF/AVG creation (CMR cohort) 
Enrolment 
Excluded: 
• Did not meet 
inclusion criteria 
Excluded: 
• Declined to 
participate 
Recruitment via renal databases at 




Group B. Vascular mapping 
before AVF/AVG creation 
	
	Standard care: 
- CTA abdominal and 
aortoiliac vasculature before 
transplant listing 
Study Visit: 
1st   FeMRA abdominal and 
aortoiliac vasculature & CMR 
Study Visits: 
1st   FeMRA vascular mapping before 
AVF/AVG creation & baseline CMR 
2nd   FeMRA & CMR 6 weeks post-
AVF/AVG creation	
Informed consent (Form B) 
Standard care: 
- US vascular mapping before 
AVF/AVG creation 
 








Patient recruited to study. 
Informed consent (Form B) 
Arteriovenous fistula creation 
Venepuncture for iron contrast 
and blood tests for biomarkers 







Venepuncture for iron contrast 
⋅ FeMRA	&	CMR	
Patient recruited to study. 
Informed consent (Form A) 
Venepuncture for iron contrast 
and blood tests for biomarkers 





Conventional	 vascular	 imaging	 techniques	 are	 often	 either	 contra-indicated	 or	 only	 used	 with	
caution	 in	 chronic	 kidney	 disease	 (CKD)	 patients	 due	 to	 their	 relative	 invasiveness,	 risks	 and	 cost.	
Computed	 tomography	 angiography	 (CTA)	 requires	 radiation	 and	 nephrotoxic	 iodinated	 contrast	
which	 may	 precipitate	 significant	 worsening	 of	 renal	 function	 and	 even	 prompt	 the	 need	 for	
institution	 of	 dialysis.	 Similarly,	 in	 patients	 receiving	 maintenance	 haemodialysis	 (HD),	 contrast	
administration	 has	 the	 potential	 risk	 of	 accelerating	 a	 decline	 in	 residual	 kidney	 function.	
Additionally,	 CT	 has	 reduced	 accuracy	 for	 arterial	 diagnosis	 in	 the	 presence	 of	 arteriosclerotic	
calcification	which	is	extremely	common	in	these	patients.	Magnetic	resonance	angiography	(MRA)	
in	 patients	 with	 end-stage	 renal	 disease	 (ESRD)	 using	 linear	 chelate	 gadolinium-based	 contrast	
agents	 has	 been	 associated	 with	 the	 rare	 disease	 ‘nephrogenic	 systemic	 fibrosis’[1].	 Alternative	
imaging	 methods	 also	 have	 drawbacks:	 for	 example,	 this	 frail	 patient	 group	 has	 a	 higher	 risk	 of	
complications	 from	 conventional	 invasive	 catheter-based	 angiography	 and	 calcification	 interferes	
with	duplex	ultrasound	assessment	of	 the	peripheral	arterial	vasculature.	Other	 tests	such	as	non-




Kidney	 transplantation	 is	 the	 treatment	of	 choice	 for	most	patients	with	ESRD.	A	 large	number	of	
potential	kidney	transplant	recipients	with	established	renal	failure	have	peripheral	vascular	disease	
and	need	additional	tests	to	characterise	the	vessels	before	placement	of	a	kidney	graft.	CTA	of	the	
aortoiliac	 vasculature	 for	 identification	 of	 calcifications	 of	 the	 iliac	 arterial	 sector	 allows	 better	




been	 limited	 because	 of	 concerns	 of	 contrast-induced	 acute	 kidney	 injury	 (CI-AKI),	 especially	 in	




Doppler	 ultrasound	 is	 routinely	 used	 to	 allow	 proper	 selection	 of	 a	 target	 vessel	 with	 adequate	
luminal	 diameter	 to	 improve	 access	 outcome.	 This	 is	 readily	 available	 and	 cheap	 but	 has	 a	major	
limitation	which	 is	 the	 relative	 inability	 to	 assess	 central	 vein	 patency.	 Central	 vein	 stenosis	 (CVS)	












practice	 for	 fistula	 surveillance	 with	 an	 increasing	 number	 of	 HD	 centres	 implementing	 fistula	
surveillance	programs.	
	
Polytetrafluoroethylene	 (PTFE)	 grafts	 are	used	 for	HD	 in	patients	with	 limited	options	 for	 a	native	
access.	 Their	 survival	 is	 similar	 or	 even	 better	 compared	 to	 AVFs	 with	 1-year	 patency	 of	
approximately	 70%[6]	 though	 they	 are	 typically	 complicated	 by	 thrombosis	 requiring	 multiple	
procedures	 to	 restore	 patency.	 Different	methodologies	 are	 currently	 being	 used	 for	 surveillance	
and	monitoring	 depending	 upon	 local	 practice	 and	 expertise.	 Doppler	 ultrasound	 is	 probably	 the	
most	reproducible	and	accurate	arteriovenous	graft	(AVG)	surveillance	method	but	has	low	accuracy	
of	 identifying	 central	 vein	 stenotic	 lesions.	 Graftogram	 with	 DSA	 which	 is	 the	 conventional	
angiography	technique	has	the	advantages	of	high	spatial	and	temporal	resolution	and	the	ability	to	
intervene	 but	 is	 invasive	 with	 the	 risk	 of	 vascular	 injury	 and	 stroke,	 does	 not	 provide	 a	 three–






of	 the	 heart	 to	 increase	 the	 cardiac	 output	 following	 fistula	 creation	 may	 lead	 to	 hypotension,	
reduced	fistula	flow	and	subsequent	failure	of	maturation.			
	














Cytokines	and	pro-inflammatory	 factors	have	been	shown	to	play	central	 roles	 in	 the	activation	of	
acute	 and	 chronic	 vascular	 responses	 to	 injury[12].	 For	 example,	 thrombin	 secreted	 by	 activated	
platelets	 adhering	 to	 the	 injured	 endothelium	 triggers	 the	 release	 of	 fibroblast	 growth	 factors,	
stimulating	 smooth	 muscle	 cells	 (SMC)	 mitogenesis	 and	 chemotaxis.	 Transforming	 growth	 factor	
beta	 (TGFß),	 a	 pleiotropic	 cytokine,	 promotes	 intimal	 hyperplasia	 by	 augmenting	 neointimal	 cell	
proliferation,	 inducing	 SMC	migration	and	 stimulating	 the	 secretion	of	 fibrotic	 extracellular	matrix	
proteins[13].	 Patients	 with	 renal	 disease	 undergoing	 HD	 have	 a	 raised	 inflammatory	 profile	 with	
significantly	 increased	 high	 sensitivity	 C-reactive	 protein	 (hs-CRP),	 serum	 tumor	 necrosis	 factor-a	
(TNF-α),	 interleukin-1	 (IL-1),	 soluble	 interleukin-2	 receptor	 (s-IL2R),	 interleukin-6	 (IL-6),	 monocyte	
chemoattractant	 protein-1	 (MCP-1),	 vascular	 cell	 adhesion	molecule	 1	 (VCAM-1)	 and	 intercellular	
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iron	deficiency	anaemia	 (IDA)	eclipsed	 its	use	as	magnetic	 resonance	 (MRI)	 contrast	agent.	During	
the	 last	 decade,	 the	 identification	 of	 the	 association	 of	 nephrogenic	 systemic	 fibrosis	 (NSF)	 with	





clinical	diagnostic	 imaging.	 It	has	gained	appeal	as	a	MRI	contrast	agent	 in	patients	with	estimated	
glomerular	filtration	rates	<30mL/min/1.73m2	in	whom	other	imaging	modalities	are	contraindicated	
or	can	only	be	used	with	caution	and	there	are	reports	in	the	literature	for	its	safe	use	and	utility	in	
both	 adult[24]	 and	pediatric[25]	 patients	with	CKD.	 Ferumoxytol	metabolism	 is	 not	dependent	on	
kidney	function,	but	rather	is	removed	from	the	circulation	by	the	reticuloendothelial	system	of	the	
liver,	 spleen,	 and	 bone	 marrow.	 Additionally,	 the	 prolonged	 intravascular	 half-life	 (>14	 hours)	 of	
Ferumoxytol	allows	for	longer	image	acquisition	and	repeat	imaging,	if	necessary[21,	26,	27].	
	
The	typical	dose	used	for	 imaging	 is	15-40%	that	for	 iron	replacement,	therefore	the	safety	profile	
for	imaging	is	more	attractive	than	for	iron	replacement.	Ferumoxytol	has	been	licensed	in	the	USA	
and	 Canada	 for	 use	 in	 patients	 with	 kidney	 failure	 and	 this	 has	 important	 implications	 in	 clinical	
practice	since	the	agent	can	be	used	in	patients	with	compromised	renal	function	where	there	is	a	












CKD	are	 limited	by	 the	 risks	 for	additional	acute	kidney	 injury	and	NSF,	 respectively,	 that	must	be	
balanced	by	the	critical	nature	of	the	radiologic	study	for	the	well-being	of	the	patient.	In	addition,	
current	 techniques	have	 reduced	accuracy	 for	arterial	diagnosis	 in	 the	presence	of	arteriosclerotic	
calcification	or	have	 limitations	 in	assessing	central	vein	patency.	 In	 these	patients,	Ferumoxytol	 is	
an	alternative	agent	for	cardiovascular	assessment,	including	vessel	patency	and	course.		
	
We	 are	 proposing	 to	 apply	 novel	 techniques	 with	 MRA	 using	 intravenous	 iron	 whilst	 planning	
transplantation	or	haemodialysis	for	renal	replacement	therapy.	The	“Use	of	Ferumoxytol	enhanced	
Magnetic	Resonance	Angiography	for	cardiovascular	assessment	in	late-stage	chronic	kidney	disease	
(FeMRA	 in	 CKD)	 study”	 is	 a	 single	 centre	 prospective	 cohort	 study	designed	 to	 compare	 routinely	
used	imagining	techniques	with	FeMRA	in	patients	with	severely	impaired	renal	function.	
	
Study	 participants	 undergoing	 standard	 imaging	 tests	 as	 part	 of	 their	 clinical	 care	 will	 also	 have	
FeMRA.	We	will	compare	outcomes	of	interest	including	quality	of	image	and	diagnostic	accuracy	in	
a	 head-to-head	 design.	 The	 additional	 information	 gained	 will	 determine	 if	 Ferumoxytol-based	

















1. Vascular	 anatomy	 before	 implantation	 of	 a	 kidney	 graft	 using	 routine	 and	 novel	 imaging	
techniques.	
	
















4. Assessment	 of	 cardiac	 anatomy,	 function,	 and	 myocardial	 perfusion	 before	 and	 after	
synthetic	graft	creation	using	novel	imaging	techniques.	
	










1. FeMRA	 is	 superior	 to	 CTA	 for	 characterisation	 of	 abdominal	 and	 aortoiliac	 anatomy	 (pre-
transplant	assessment)	before	implantation	of	a	kidney	graft.	
	




3. FeMRA	 is	 superior	 to	 Doppler	 US	 for	 characterisation	 of	 upper	 limb	 vascular	 anatomy	
(vascular	mapping)	before	synthetic	graft	creation.	
	
4. FeMRA	 is	 superior	 to	 Doppler	 US	 for	 characterisation	 of	 upper	 limb	 vascular	 anatomy	
(vascular	mapping)	before	fistula	creation	in	patients	with	suspected	CVS.	
	
5. FeMRA	 is	 superior	 to	 Doppler	 US	 for	 characterisation	 of	 upper	 limb	 vascular	 anatomy	
(vascular	mapping)	before	synthetic	graft	creation	in	patients	with	suspected	CVS.	
	
6. FeMRA	 is	 superior	 to	 Doppler	 US	 for	 characterisation	 of	 fistula	 arm	 vascular	 anatomy	
(surveillance)	at	6	weeks	after	fistula	creation.	
	














(vascular	 mapping)	 associated	 with	 fistula	 (or	 graft)	 outcomes	 in	 patients	 with	 suspected	
CVS.	
 















2. FeMRA	 has	 the	 advantage	 of	 complete	 cardiovascular	 assessment	 (heart,	 central,	 and	
peripheral	 vasculature)	 using	 a	 single	 imaging	 modality	 when	 used	 for	 pre-transplant	
assessment.	
	

















































































Pre-operative	 and	 post-operative	 FeMRAs	 will	 be	 performed	 by	 trained	 personnel	 using	
standardised	protocols.	 FeMRAs	will	 be	 reviewed	by	 the	 study	 radiologists	who	will	 be	blinded	 to	












The	 imaging	 studies	 will	 serve	 multiple	 functions	 including	 characterising	 the	 natural	 history	 of	
fistula	maturation	 and	delineating	 temporal	 changes	 that	 reflect	 physiological	 responses	 to	 fistula	
(or	 graft)	 creation.	 The	 6-week	 ultrasound	 (and	 FeMRA)	 will	 be	 used	 to	 predict	 imaging-based	
	19	
	
anatomical	 maturation	 as	 a	 potential	 surrogate	 for	 clinical	 maturation.	 One	 study	 objective	 is	 to	
determine	 if	 FeMRA	 is	 superior	 to	 ultrasound	 in	 characterisation	 of	 blood	 vessel	 anatomy	 and	
demonstration	 of	 subtle	 arterial	 and	 venous	 changes	 prior	 to	 these	 having	 haemodynamic	
significance.	Another	objective	 is	 to	determine	 the	utility	of	 fistula	 luminal	diameter,	 inflow	artery	






cephalic	 and	 basilic	 veins	 at	 the	 proximal	 upper	 arm,	 mid-upper	 arm,	 distal	 upper	 arm,	 and	
antecubital	fossa;	cephalic	vein	at	the	proximal	forearm,	mid-forearm,	distal	forearm,	and	the	wrist.	
Compressibility	 and	 presence	 of	 thrombus	 as	 well	 as	 continuity	 to	 the	 upper	 arm	 deep	 venous	
vasculature	 will	 be	 assessed.	 Vein-US	 examinations	 will	 be	 performed	 with	 the	 patient	 supine	 at	
ambient	temperature	and	a	rubber	tourniquet	in	place.	Specific	arterial-US	examination	components	
include:	diameter	of	the	brachial	artery	at	the	antecubital	fossa,	diameter	of	the	radial	artery	at	the	
wrist,	 level	of	brachial	artery	bifurcation	 relative	 to	 the	antecubital	 fossa,	 results	of	 the	US	Allen's	
test,	 and	 arterial	 waveform	 tracing	 at	 the	 antecubital	 fossa	 brachial	 artery	 and	 the	 wrist	 radial	
artery.	The	US	Allen's	test	will	be	performed	as	described	by	the	American	Institute	of	Ultrasound	in	
Medicine	(AIUM)	Practice	Guidelines[29]	by	occluding	the	radial	artery	near	the	wrist	and	placing	the	










Patients	 will	 undergo	 MRA	 with	 Ferumoxytol	 administered	 in	 an	 appropriate	 setting	 under	
supervision	 of	 trained	 medical	 personnel	 with	 appropriate	 monitoring	 and	 resuscitation	 facilities	
immediately	available.	
	
We	 are	 proposing	 to	 perform	 FeMRA	 to	 assess	 central	 and	 peripheral	 vessels,	 and	 the	 heart	
depending	on	 the	 indication.	 Images	will	be	acquired	while	 the	patient	 remains	 supine	 in	 the	MRI	
system	 (3T	 Prisma	 at	 Glasgow	 Clinical	 Research	 Facility	 on	 Queen	 Elizabeth	 University	 Hospital	
campus)	with	local	phased	array	imaging	coils.	The	scan	will	last	for	approximately	45	minutes.	
	
We	will	place	an	 intravenous	cannula	during	 the	course	of	 the	 research	scan	 for	administration	of	
the	dilute	Ferumoxytol	 infusion.	Blood	samples	will	be	obtained	at	the	time	of	cannula	placement.	





The	 patient	 will	 be	 monitored	 by	 medical	 and	 radiographic	 staff	 at	 baseline,	 during,	 and	 for	 a	
minimum	 period	 of	 30	 minutes	 following	 termination	 of	 infusion.	 Patients	 will	 be	 instructed	 to	
immediately	alert	the	operator	should	they	have	any	feelings	of	discomfort	at	any	time.	Patients	will	
be	continuously	monitored	by	pulse	oximetry	while	in	the	MRI	scanner	and	will	have	blood	pressure	
and	 pulse	 measured	 before	 and	 after	 infusions.	 Administration	 of	 other	 medications	 that	 could	
potentially	cause	serious	hypersensitivity	 reactions	and/or	hypotension,	 such	as	chemotherapeutic	




already	 out	 of	 the	 scanner.	 Once	 out	 of	 the	 scanner,	 patients	 will	 remain	 in	 a	 reclining	 or	 semi-
reclining	 position.	 Observation	 for	 the	 full	 30	 minutes	 following	 the	 contrast	 injection,	 i.e.,	 both	
while	the	patient	is	in	the	scanner	and	following	that	will	be	done	by	the	doctors	directly	involved	in	
the	study	who	are	aware	of	the	study	protocol,	and	who	are	trained	on	procedures	to	be	followed	in	
the	 event	 of	 any	 reaction.	 The	 same	 precautions	 will	 be	 taken	 for	 each	 scan,	 even	 if	 no	





3mg	 of	 Ferumoxytol/kg	 of	 patient	 weight	 will	 be	 delivered	 (not	 to	 exceed	 300mg).	 In	 all	 cases	
Ferumoxytol	will	be	diluted	to	a	concentration	no	greater	than	1	part	Ferumoxytol	to	4	parts	0.9%	
sodium	 chloride.	 Ferumoxytol	 administration	 is	 controlled	 by	 a	 sophisticated	 MRI	 compatible	
infusion	pump	for	precise	control	over	infusion	rate.	When	given	for	treatment	of	IDA,	the	licensed	
dose	of	Ferumoxytol	 is	an	 initial	510mg	dose	administered	as	an	 intravenous	 infusion	 in	50-200mL	
0.9%	sodium	chloride	or	5%	Dextrose	over	at	least	15	minutes,	followed	by	a	second	510mg	dose	3	
to	8	days	later.	When	administered	for	imaging,	Ferumoxytol	will	be	given	in	a	continuous	infusion	




group	 will	 be	 rounded	 up	 to	 the	 dose	 required	 for	 the	 upper	 limit	 of	 the	 group.	 The	 average	
rounding	is	a	6%	increase	in	dose	(range	4-13%)	compared	to	actual	dose	at	the	lowest	weight	of	the	





is	 optional	 and	will	 not	 affect	 patients’	 participation	 in	 the	main	 study.	 In	 this	 sub-study,	we	will	
acquire	 additional	 cardiac	MRI	 scans	 at	 our	University	MRI	 site	 (Glasgow	Cardiovascular	 Research	
Centre,	British	Heart	Foundation	Centre	of	Excellence).	This	additional	scan	will	give	us	information	
about	 the	 status	 of	 epicardial	 coronary	 vessels	 and	 provide	 a	 detailed	 4D	 magnetic	 resonance	
angiography	dataset	(3D	coronary	vessel	tree	in	multiple	ECG	phases).	This	method	was	developed	
by	our	collaborators	at	 the	Cedars	Sinai	Hospital,	USA,	and	will	 allow	us	 to	have	a	complete,	non-
invasive	assessment	of	 the	heart	morphology	and	different	 levels	of	 function:	 from	the	patency	of	
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at	 the	 British	 Heart	 Foundation	 scanner	 (following	 their	 FeMRA	 scan	 at	 the	 Queen	 Elizabeth	
University	Hospital).	No	additional	contrast	administration	is	required	for	the	4D	coronary	MRA	scan	
which	will	 last	 for	 approximately	 60	minutes.	 Patients	 that	will	 consent	will	 be	 offered	 lunch	 and	





Venous	blood	will	 be	 collected	at	baseline	and	at	6	weeks	after	 fistula	 (or	 graft)	 creation.	Venous	
blood	will	be	analysed	for	vascular	biomarkers,	which	may	include	TGFß,	high	sensitivity	troponin	I	
(hs-TNI),	pentraxin	3,	 ICAM-1,	von	Willebrand	factor	 (vWF),	 tissue	plasminogen	activator	 (tPA)	and	
plasminogen	 activator	 inhibitor-1	 (PAI-1).	 Novel	 biomarkers	 of	 endothelial	 function	 continue	 to	




anonymised	 in	 the	 laboratory.	 No	 identifiable	 details	 will	 be	 collected	 with	 the	 samples.	 If	
agreement	is	given	for	potential	novel	biomarkers,	10ml	of	blood	will	be	anonymously	stored	–	any	
subsequent	 analysis	 of	 these	 samples	will	 be	 subject	 to	 approval	 of	 a	 Research	 Ethics	 Committee	
prior	to	analysis.	On	the	completion	of	this	study,	the	blood	samples	will	be	transferred	and	retained	






fistula	 creation	 as	 at	 that	 point	 it	 is	 generally	 apparent	 whether	 a	 fistula	 will	 mature	 without	
additional	intervention[30,	31].	
	
Participants	will	 be	provided	with	a	patient	 information	 sheet	 (PIS)	 and	given	at	 least	24	hours	 to	
consider	 their	 response	 before	 consent	 is	 taken	 and	 a	 screening	 visit	 is	 performed	 to	 check	 their	
eligibility	by	all	the	criteria.	Standard	imaging	tests	will	take	place	as	part	of	the	routine	clinical	care.	
The	FeMRA	scan	will	be	requested	and	scheduled	at	a	suitable	date	and	time	-	usually	the	scan	will	
be	 within	 two	 weeks	 after	 they	 sign	 the	 consent	 form.	 For	 practical	 reasons,	 the	 scans	 will	 be	















The	 participant	 would	 only	 be	 in	 the	 study	 in	 person	 up	 to	 the	 completion	 of	 the	 study	
















































(combined	 oral	 contraceptives,	 progesterone	 only	 contraceptives,	 intrauterine	 device,	 and	
barrier	 methods)	 or	 they	 are	 abstinent	 due	 to	 lifestyle	 choice	 or	 their	 partner	 is	 sterile	
(vasectomy).	
	
4. Standard	 contra-indications	 to	MRI:	 the	 presence	 of	 certain	metallic	 objects	 in	 the	 body	 (e.g.	




asthma,	eczema,	atopy,	patients	with	 immune	or	 inflammatory	conditions	(e.g.	systemic	 lupus,	
rheumatoid	 arthritis),	 any	 conditions	 associated	 with	 iron	 overload	 (e.g.	 haemochromatosis,	









entry	 to	 the	 study	 prior	 to	 obtaining	written	 consent	 and	 all	 efforts	will	 be	made	 to	 ensure	 that	
patients	understand	the	commitment	required	to	fulfill	the	study	requirements.	Patients	will	also	be	
made	aware	 that	participation	 is	 voluntary	and	 that	 they	can	 leave	 the	 study	at	any	 time	without	
their	standard	care	being	affected.	
	
The	 participant	 will	 be	 informed	 and	 must	 agree	 to	 their	 medical	 records	 being	 inspected	 by	











Ferumoxytol	 is	 specifically	 licensed	 for	 the	 treatment	of	 IDA	 in	patients	with	CKD.	This	 is	currently	
used	 in	 the	USA	and	Canada	but	not	 in	Europe	as	 the	company	has	withdrawn	 the	drug	 from	the	
market	purely	 for	 commercial	 reasons.	Nonetheless,	 Ferumoxytol	 is	 still	 available	 in	 the	UK	and	 is	
used	 as	 an	 unlicensed	medicine	 for	 imaging	 purposes.	 As	 with	 any	medicinal	 compound	 there	 is	
potential	for	adverse	reactions,	though	the	rates	of	these	in	clinical	trials	and	post-marketing	safety	
data	 on	 therapeutic	 use	 of	 Ferumoxytol	 are	 very	 low[23,	 32-34].	 The	 main	 concern	 has	 been	
reported	 cases	 of	 'anaphylactic'	 type	 reactions	 with	 therapeutic	 bolus	 injections	 of	 undiluted	
compound	 leading	 to	 the	 recent	 recommendations	 for	 controlled	 infusion	 of	 dilute	 Ferumoxytol.	






careful	 monitoring	 of	 patients	 during	 the	 infusions	 and	 following	 scans	 patients	 will	 undergo	 a	
period	of	close	observation.	
	
We	 have	 experience	 with	 the	 use	 of	 Ferumoxytol	 in	 a	 study	 investigating	 a	 different	 imaging	
property	 in	 greater	 than	 600	 subjects.	 No	 serious	 adverse	 events	 were	 recorded.	 We	 have	 also	
undertaken	 clinically	 indicated	 MRI	 scans	 using	 Ferumoxytol	 as	 contrast	 agent	 in	 an	 expanding	
cohort	 of	 patients	 with	 advanced	 renal	 failure	 in	 whom	 other	 imaging	 methods	 have	 proven	
problematic.	Other	centres	performing	similar	MRI	work	have	seen	no	instances	of	this	type	of	acute	
adverse	 reaction	 in	 large	 (>100)	 cohorts	 of	 patients.	 A	 recent	 survey	 (05/2015)	 of	 all	 sites	 using	




It	 is	 important	 to	 note	 that	 the	 above	 risks	 have	 parity	 with	 the	 other	 commonly	 administered	
intravenous	 radiological	 contrast	 media	 (whether	 iodine	 or	 gadolinium-based).	 Patients	 will	
therefore	not	be	exposed	to	disproportionate	risk.	
	







MRI	 studies	may	 persist	 for	 up	 to	 3	months	 following	 infusion.	 This	 is	 the	 case	 when	 the	 higher	







weighted	MR	 pulse	 sequences	 to	minimise	 the	 Ferumoxytol	 effects	will	 be	 performed;	MRI	 using	




this	 is	 not	different	of	what	happens	when	 intravenous	 iron	 (any	preparation)	 is	 administered	 for	
therapeutic	purposes.	The	information	of	iron	administration	as	a	contrast	agent	will	be	available	to	






















All	 referrals	 for	 imaging	are	made	through	password-protected	software.	The	referrals	can	only	be	
read	 by	 password-protected	 software.	 The	 imaging	 data	 obtained	 from	 the	 study	 is	 recorded	 on	
computers	 within	 a	 building	 with	 secure	 access.	 These	 computers,	 and	 the	 imaging	 software	 on	







The	primary	outcome	 is	comparison	of	FeMRA	with	standard	 imaging	techniques	 in	assessment	of	
vascular	 anatomy.	 Multiple	 cross	 sections	 of	 various	 vascular	 beds	 obtained	 with	 currently	 used	
imaging	 techniques	 will	 be	 compared	 with	 matched	 sections	 obtained	 with	 FeMRA	 in	 a	 blinded	













2. Fistula	 or	 graft	 complications:	 stenosis,	 thrombosis,	 hand	 ischaemia,	 aneurysm	 or	
pseudoaneurysm,	infiltration,	fistula	bleeding,	and	infection.	
	
3. Fistula	or	graft	procedures:	surgical	 revision,	angioplasty,	stent	placement,	 thrombolysis	or	
thrombectomy,	 ligation	of	 accessory	 veins,	 superficialisation	of	 vein,	 transposition	of	 vein,	
central	venous	catheter	use,	and	placement	of	new	arteriovenous	access.	
 

















The	 data	 will	 be	 collected	 by	 the	 research	 fellow	 (CI)	 on	 paper	 with	 subsequent	 transcription	 to	





drives,	 accessed	 by	 members	 of	 the	 primary	 research	 team	 only.	 Each	 patient	 will	 have	 a	 CRF	
created	with	the	link	to	this	held	in	a	locked	office	in	BHF	Cardiovascular	Research	Building.	Clinical	
imaging	data	will	be	stored	on	the	National	PACS	and	will	remain	stored	on	this	password-protected	











The	 general	 analytical	 approach	 will	 be	 to	 estimate	 accuracy	 (95%	 CI),	 sensitivity	 (95%	 CI)	 and	
specificity	(95%	CI)	of	FeMRA	and	standard	imaging	techniques.	 In	addition,	Cohen’s	κ	with	95%	CI	
will	be	computed	 to	compare	arterial	 sections	 that	 can	be	assessed	with	both	 imaging	 techniques	





Because	multiple	 image	 locations	 from	 each	 patient	will	 be	 used	 for	 the	 statistical	 evaluation	 (at	










sufficient	 to	confirm	our	 study	hypothesis.	 From	these	patients,	8	were	 in	group	A,	and	9	were	 in	
group	B.				
	





FeMRA	 identified	 2%	more	 significant	 arterial	 stenoses	 compared	 with	 US.	 There	 was	 very	 good	
agreement	on	assessment	of	 image	quality	 in	arteries	between	FeMRA	and	CTA	 (kappa=0.85)	and	
moderate	 agreement	 between	 FeMRA	 and	 US	 (kappa=0.65).	 On	 assessment	 of	 the	 venous	
vasculature,	5%	more	anatomical	 characteristics	of	 significance	 (i.e.	 stenosis,	occlusion,	 aneurysm,	












predictors	 will	 be	 treated	 as	 uniform	 across	 all	 anatomical	 configurations	 unless	 there	 is	 strong	








Any	changes	 to	 the	 final	approved	protocol	will	 require	an	amendment.	The	CI	will	 liaise	with	 the	
sponsor	to	determine	whether	an	amendment	is	substantial	or	non-substantial.	Amendments	to	the	
protocol	will	 be	 submitted	 in	writing	 to	 the	 Sponsor	 for	 approval	 prior	 to	 being	 submitted	 to	 the	
appropriate	REC,	Regulatory	Authority	and	local	NHS	Research	and	Development	(R&D)	for	approval.	








In	 the	 event	 that	 any	 study	 investigator	 needs	 to	 deviate	 from	 the	 protocol,	 the	 nature	 of	 and	
reasons	for	the	deviation	will	be	recorded	 in	the	CRF,	documented	 in	a	Breaches	&	Deviations	Log	
and	 submitted	 to	 the	Sponsor.	 If	 this	necessitates	a	 subsequent	protocol	 amendment,	 this	will	 be	









audit	 schedule.	 The	 CI	 will	 permit	 trial	 related	 monitoring,	 audits,	 REC	 review,	 and	 regulatory	

































The	 clinical	 study	 report	 will	 be	 used	 for	 publication	 and	 presentation	 at	 scientific	 meetings.	
Investigators	 have	 the	 right	 to	 publish	 orally	 or	 in	writing	 the	 results	 of	 the	 study.	 Summaries	 of	







Peer	 review	 of	 the	 protocol	 will	 occur	 via	 the	 Sponsorship	 Committee	 and	 of	 the	 resulting	
publication	by	the	referees	of	the	journal	to	which	the	paper	(and	its	protocol)	will	be	submitted.	
	









• Adverse	Reaction	 (AR):	 any	untoward	and	unintended	response	 in	a	 subject	 to	a	 research	
product	which	is	related	to	any	dose	administered	to	that	subject.	
• Serious	Adverse	Event	Reporting:	a	Serious	Adverse	Event	(SAE)	is	defined	as	an	untoward	
occurrence	 that:	 (a)	 results	 in	 death;	 (b)	 is	 life-threatening;	 (c)	 requires	 hospitalisation	 or	










Where	 an	 SAE	 requires	 recording,	 full	 details	 should	 be	 documented	 including	 the	 nature	 of	 the	
event,	start	and	stop	dates,	severity,	relationship	to	research	product	and/or	procedures.	Outcome	
will	 be	 recorded	 in	 the	 patient’s	 CRF	 and	 medical	 notes.	 These	 events	 will	 be	 monitored	 and	
























Reports	 of	 SARS	 and	 SAEs	 should	 be	 submitted	 within	 15	 days	 of	 the	 CI	 becoming	 aware	 of	 the	
event,	 using	 the	 ‘report	 of	 serious	 adverse	 event	 form’	 for	 non-CTIMPs	 published	 on	 the	 Health	
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40-45	 135	 4.5	 18.0	 22.5	
46-50	 150	 5.0	 20.0	 25.0	
51-55	 165	 5.5	 22.0	 27.5	
56-60	 180	 6.0	 24.0	 30.0	
61-65	 195	 6.5	 26.0	 32.5	
66-70	 210	 7.0	 28.0	 35.0	
71-75	 225	 7.5	 30.0	 37.5	
76-80	 240	 8.0	 32.0	 40.0	
81-85	 255	 8.5	 34.0	 42.5	
86-90	 270	 9.0	 36.0	 45.0	
91-95	 285	 9.5	 38.0	 47.5	
96-100	 300	 10.0	 40.0	 50.0	































Arterial	vasculature	 Vein	 mapping	 (peripheral	
veins)	
Inflow	 artery	 proximal	 to	 the	
fistula	or	graft	
Abdominal	aorta	 Cephalic	 vein	 at	 the	 proximal	
upper	arm	
Inflow	 artery	 distal	 to	 the	
fistula	or	graft	
Coeliac	artery	 Cephalic	 vein	 at	 the	mid-upper	
arm	
Anastomotic	 sites	 (fistula	 has	
one	site,	graft	has	two	sites)	





Outflow	 vein	 proximal	 to	 the	
fistula	or	graft	
Renal	arteries	 Cephalic	 vein	 at	 the	 proximal	
forearm	
Outflow	 vein	 middle	 to	 the	
fistula	or	graft	
Common	iliac	arteries	 Cephalic	 vein	 at	 the	 mid-
forearm	
Outflow	 vein	 distal	 to	 the	
fistula	or	graft	







































	 Level	 of	 brachial	 artery	
bifurcation	 relative	 to	 the	
antecubital	fossa	
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Table	3.	Anatomical	characteristics	or	lesions	to	be	assessed	
	
Artery	diameter	
Vein	diameter	
Stenosis	
Occlusion	
Vessel	irregularity	
Luminal	narrowing	
Wall	thickening	
Calcification	
Aneurysm/pseudoaneurysm	
Presence	of	thrombus	
	
Fistula	(or	graft)	specific	
Vein	depth	from	skin	surface	
Fistula	(or	graft)	diameter	
Fistula	(or	graft)	stenosis	
Fistula	(or	graft)	thrombosis	
Inflow	stenosis	
Outflow	stenosis	
Length	of	straight	segment	for	cannulation	
Blood	flow	rate	
	
